Zobrazeno 1 - 10
of 265
pro vyhledávání: '"Jason K. Sicklick"'
Multi‐omic analysis in carcinoma of unknown primary (CUP): therapeutic impact of knowing the unknown
Autor:
Shumei Kato, Sophia Gumas, Jacob J. Adashek, Ryosuke Okamura, Suzanna Lee, Jason K. Sicklick, Razelle Kurzrock
Publikováno v:
Molecular Oncology, Vol 18, Iss 4, Pp 956-968 (2024)
Carcinoma of unknown primary (CUP) is a difficult‐to‐manage malignancy. Multi‐omic profiles and treatment outcome vs. degree of precision matching were assessed. Tumours underwent next‐generation sequencing (NGS) [tissue and/or blood‐derive
Externí odkaz:
https://doaj.org/article/2f709749a5e648c68c0ec4e1799e0aa3
Autor:
Hirotaka Miyashita, Razelle Kurzrock, Nicholas J. Bevins, Kartheeswaran Thangathurai, Suzanna Lee, Sarabjot Pabla, Mary Nesline, Sean T. Glenn, Jeffrey M. Conroy, Paul DePietro, Eitan Rubin, Jason K. Sicklick, Shumei Kato
Publikováno v:
npj Genomic Medicine, Vol 8, Iss 1, Pp 1-10 (2023)
Abstract Immune checkpoint blockade is effective for only a subset of cancers. Targeting T-cell priming markers (TPMs) may enhance activity, but proper application of these agents in the clinic is challenging due to immune complexity and heterogeneit
Externí odkaz:
https://doaj.org/article/9b9d07a8e8b84b69aa3ad5d3d41c13e8
Autor:
Justin Shaya, Shumei Kato, Jacob J. Adashek, Hitendra Patel, Paul T. Fanta, Gregory P. Botta, Jason K. Sicklick, Razelle Kurzrock
Publikováno v:
npj Genomic Medicine, Vol 8, Iss 1, Pp 1-8 (2023)
Abstract Despite progress, 2-year pancreatic cancer survival remains dismal. We evaluated a biomarker-driven, combination/N-of-one strategy in 18 patients (advanced/metastatic pancreatic cancer) (from Molecular Tumor Board). Targeted agents administe
Externí odkaz:
https://doaj.org/article/a2de75649db9401d9bfbe553e7066915
Autor:
Bryan H. Louie, Shumei Kato, Ki Hwan Kim, Hyo Jeong Lim, Ryosuke Okamura, Ramez N. Eskander, Gregory Botta, Hitendra Patel, Suzanna Lee, Scott M. Lippman, Jason K. Sicklick, Razelle Kurzrock
Publikováno v:
npj Precision Oncology, Vol 6, Iss 1, Pp 1-8 (2022)
Abstract Despite remarkable responses to immune checkpoint blockade (ICB) in some advanced cancers, most patients do not benefit, perhaps due to the complexity of tumor/immune/genome interactions. We implemented a multidisciplinary Molecular Tumor Bo
Externí odkaz:
https://doaj.org/article/87417e472ac440e38d8c32f273271ffa
Autor:
Hanna E. Persha, Shumei Kato, Pradip De, Jacob J. Adashek, Jason K. Sicklick, Vivek Subbiah, Razelle Kurzrock
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-5 (2022)
Abstract There is a paucity of information about molecularly driven therapy in osteosarcomas. We report a 31-year-old woman with chemotherapy–refractory metastatic osteosarcoma who was successfully treated with the combination of palbociclib (CDK4/
Externí odkaz:
https://doaj.org/article/9569186ceeb542d5af064c6816ae1426
Autor:
Diviya Gupta, Razelle Kurzrock, Suzanna Lee, Ryosuke Okamura, Hyo Jeong Lim, Ki Hwan Kim, Jason K. Sicklick, Shumei Kato
Publikováno v:
npj Precision Oncology, Vol 6, Iss 1, Pp 1-5 (2022)
Abstract Though advanced cancers generally display complex molecular portfolios, there is a subset of patients whose malignancies possess only one genomic alteration or alterations in one oncogenic pathway. We assess how N-of-One therapeutic strategi
Externí odkaz:
https://doaj.org/article/17dfc439d3ba44ecb82504f30b7f3d23
Autor:
Jason K. Sicklick, Shumei Kato, Ryosuke Okamura, Hitendra Patel, Mina Nikanjam, Paul T. Fanta, Michael E. Hahn, Pradip De, Casey Williams, Jessica Guido, Benjamin M. Solomon, Rana R. McKay, Amy Krie, Sarah G. Boles, Jeffrey S. Ross, J. Jack Lee, Brian Leyland-Jones, Scott M. Lippman, Razelle Kurzrock
Publikováno v:
Genome Medicine, Vol 13, Iss 1, Pp 1-14 (2021)
Abstract Background Malignancies are molecularly complex and become more resistant with each line of therapy. We hypothesized that offering matched, individualized combination therapies to patients with treatment-naïve, advanced cancers would be fea
Externí odkaz:
https://doaj.org/article/ce82766f53714708a38b7c9764d67487
Autor:
Hyunho Yoon, Chih-Min Tang, Sudeep Banerjee, Antonio L. Delgado, Mayra Yebra, Jacob Davis, Jason K. Sicklick
Publikováno v:
Oncogenesis, Vol 10, Iss 2, Pp 1-12 (2021)
Abstract Cancer-associated fibroblasts (CAFs) are the most abundant cells in the tumor microenvironment. Crosstalk between tumor cells and CAFs contributes to tumor survival in most epithelial cancers. Recently, utilizing gastrointestinal stromal tum
Externí odkaz:
https://doaj.org/article/a3983b4662a5420fa321120c6a1a0a59
Autor:
Brennan Marsh-Armstrong, Jula Veerapong, Michael Taddonio, Sarah Boles, Jason K. Sicklick, Pratibha Binder
Publikováno v:
Gynecologic Oncology Reports, Vol 39, Iss , Pp 100901- (2022)
Externí odkaz:
https://doaj.org/article/c9a02ade7b2b426ca8cc74bb1ea61c58
Autor:
Shumei Kato, Ki Hwan Kim, Hyo Jeong Lim, Amelie Boichard, Mina Nikanjam, Elizabeth Weihe, Dennis J. Kuo, Ramez N. Eskander, Aaron Goodman, Natalie Galanina, Paul T. Fanta, Richard B. Schwab, Rebecca Shatsky, Steven C. Plaxe, Andrew Sharabi, Edward Stites, Jacob J. Adashek, Ryosuke Okamura, Suzanna Lee, Scott M. Lippman, Jason K. Sicklick, Razelle Kurzrock
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-9 (2020)
A molecular tumor board (MTB) is often used as a platform that integrates clinical and molecular parameters for clinical decision making. Here, the authors review the outcome of 715 cancer patients presented at their institution’s MTB, and demonstr
Externí odkaz:
https://doaj.org/article/be2daa0bb1884adbb304041e571d8edf